Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Ayman Al‐Shurbaji"'
Autor:
Jean‐Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al‐Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Béla Merkely, John J.V. McMurray, Marc A. Pfeffer
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1066-1076 (2023)
Abstract Aims Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sod
Externí odkaz:
https://doaj.org/article/3f9decbc19424144b1f6cdc8f26cf6c0
Autor:
Michel Jadoul, Steven Fishbane, Laura Dember, CP Kovesdy, Ayman Al-Shurbaji, Vera Lisovskaja, Priya Sekar, Brian Katona, Nicolas Guzman, Charles Herzog
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Introduction Patients with kidney failure receiving chronic haemodialysis have elevated risk of arrhythmias potentially increasing the likelihood of sudden cardiac death, stroke and hospitalisation. The DIALIZE study (NCT03303521) demonstrated that s
Externí odkaz:
https://doaj.org/article/88fbd23c4438451989c68202499abdea
Autor:
Steven Fishbane, Martin Ford, Masafumi Fukagawa, Kieran McCafferty, Anjay Rastogi, Bruce Spinowitz, Konstantin Staroselskiy, Konstantin Vishnevskiy, Vera Lisovskaja, Ayman Al-Shurbaji, Nicolas Guzman, Sunil Bhandari
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Sodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance hemodialysis patients. In post-hoc analyses of the phase 3b DIALIZE study, we examined the spectrum of potassium res
Externí odkaz:
https://doaj.org/article/34d28eb0545844c79c1ba2ef8a4c4182
Autor:
Jean‐Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al‐Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Béla Merkely, John J.V. McMurray, Marc A. Pfeffer
Publikováno v:
ESC Heart Failure. 10:1066-1076
Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin-angiotensin-aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cycl
Publikováno v:
Clinical Kidney Journal. 16:151-158
Background Sodium zirconium cyclosilicate (SZC) is an oral, highly selective potassium binder approved for the treatment of hyperkalaemia in adults. SZC may change the absorption of co-administered drugs that exhibit pH-dependent bioavailability. Thi
Autor:
Steven Fishbane, Martin Ford, Masafumi Fukagawa, Kieran McCafferty, Anjay Rastogi, Bruce Spinowitz, Konstantin Staroselskiy, Konstantin Vishnevskiy, Vera Lisovskaja, Ayman Al-Shurbaji, Nicolas Guzman, Sunil Bhandari
Publikováno v:
Kidney International Reports. 7:908-912
Autor:
Steven Fishbane, Michel Jadoul, Laura Dember, CP Kovesdy, Ayman Al-Shurbaji, Vera Lisovskaja, Priya Sekar, Brian Katona, Nicolas Guzman, Charles Herzog
Publikováno v:
BMJ open, Vol. 13, no.5, p. e071309 (2023)
IntroductionPatients with kidney failure receiving chronic haemodialysis have elevated risk of arrhythmias potentially increasing the likelihood of sudden cardiac death, stroke and hospitalisation. The DIALIZE study (NCT03303521) demonstrated that so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05101376db7aaf645a7804cd8011a9d4
https://hdl.handle.net/2078.1/275138
https://hdl.handle.net/2078.1/275138